Howland E Crosswell, MD | Greenville ...

Dr. Howland Crosswell

Claim this profile

Saint Francis Cancer Center

Studies Hodgkin's Lymphoma
Studies Leukemia
17 reported clinical trials
46 drugs studied

Area of expertise

1

Hodgkin's Lymphoma

Howland Crosswell has run 4 trials for Hodgkin's Lymphoma. Some of their research focus areas include:

Stage IV
Stage III
Stage I
2

Leukemia

Howland Crosswell has run 3 trials for Leukemia. Some of their research focus areas include:

Stage II
Stage III
Stage IV

Affiliated Hospitals

Image of trial facility.

Saint Francis Hospital

Image of trial facility.

Saint Francis Cancer Center

Clinical Trials Howland Crosswell is currently running

Image of trial facility.

Chemotherapy

for Cancer

This phase III trial studies how well active surveillance help doctors to monitor subjects with low risk germ cell tumors for recurrence after their tumor is removed. When the germ cell tumor has spread outside of the organ in which it developed, it is considered metastatic. Chemotherapy drugs, such as bleomycin, carboplatin, etoposide, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. The trial studies whether carboplatin or cisplatin is the preferred chemotherapy to use in treating metastatic standard risk germ cell tumors.

Recruiting

2 awards

Phase 3

26 criteria

Image of trial facility.

Levocarnitine

for Chemotherapy-Related Liver Protection in Leukemia and Lymphoma

This phase III trial compares the effect of adding levocarnitine to standard chemotherapy versus (vs.) standard chemotherapy alone in protecting the liver in patients with leukemia or lymphoma. Asparaginase is part of the standard of care chemotherapy for the treatment of acute lymphoblastic leukemia (ALL), lymphoblastic lymphoma (LL), and mixed phenotype acute leukemia (MPAL). However, in adolescent and young adults (AYA) ages 15-39 years, liver toxicity from asparaginase is common and often prevents delivery of planned chemotherapy, thereby potentially compromising outcomes. Some groups of people may also be at higher risk for liver damage due to the presence of fat in the liver even before starting chemotherapy. Patients who are of Japanese descent, Native Hawaiian, Hispanic or Latinx may be at greater risk for liver damage from chemotherapy for this reason. Carnitine is a naturally occurring nutrient that is part of a typical diet and is also made by the body. Carnitine is necessary for metabolism and its deficiency or absence is associated with liver and other organ damage. Levocarnitine is a drug used to provide extra carnitine. Laboratory and real-world usage of the dietary supplement levocarnitine suggests its potential to prevent or reduce liver toxicity from asparaginase. The overall goal of this study is to determine whether adding levocarnitine to standard of care chemotherapy will reduce the chance of developing severe liver damage from asparaginase chemotherapy in ALL, LL and/or MPAL patients.

Recruiting

2 awards

Phase 3

More about Howland Crosswell

Clinical Trial Related

6 years of experience running clinical trials · Led 17 trials as a Principal Investigator · 8 Active Clinical Trials

Treatments Howland Crosswell has experience with

  • Cyclophosphamide
  • Brentuximab Vedotin
  • Vincristine Sulfate
  • Nivolumab
  • Doxorubicin Hydrochloride
  • Rituximab

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does Howland Crosswell specialize in?

Is Howland Crosswell currently recruiting for clinical trials?

Are there any treatments that Howland Crosswell has studied deeply?

What is the best way to schedule an appointment with Howland Crosswell?

What is the office address of Howland Crosswell?

Is there any support for travel costs?